Europe Cancer Biomarkers Market - Growth, Trends and Forecasts

1. INTRODUCTION

1.1 Objective

1.2 Key findings and observations

1.3 Research methodology

1.4 Market stakeholders

  2. EXECUTIVE SUMMARY  

3. MARKET OVERVIEW

3.1 Definition of the market

3.2 Market growth estimation

3.3 Market size estimation

3.4 Classification of Cancer biomakers

3.5 Technologies used in Identifying cancer biomakers

  4. Market Dynamics

4.1 Market Drivers

4.1.1 Non invasive technologies

4.1.2 Increased survival rates

4.1.3 Enhanced accuracy and Speed of diagnosis

4.1.4 Streamlined drug delivery process

4.1.5 Helps in FDA approval of drugs

4.1.6 Boost in government and Private funds for biomarkers discovery

4.2 Market Restraints

4.2.1 High cost of diagnosis

4.2.2 Reimbursement issues

4.2.3 Need for immediate processing

  5. Biomarkers Indication Market

5.1 Oncology Biomarkers Market

5.2 Cardiology biomarkers market

5.3 Neurology biomarkers market

5.4 Others Indication Biomarkers Market

5.5 Disease types

5.6 Renal failure

5.7 Arthritis

5.8 Tuberculosis

5.9 Diabetes

  6. Europe Biomarkers market segmentation

6.1 Market segmentation, By type of application

6.1.1 Risk Assesment

6.1.2 Development of molecular diagnostics

6.1.3 Disease diagnosis

6.1.4 Drug discovery and development

6.1.5 Drug formulation

6.1.6 Forensic application

6.1.7 Others(DNA fingerprinting and others)

6.2 Market segmentation, By Services

6.2.1 Sample preparation

6.2.2 Assay developement

6.2.3 Biomakers validation and testing

6.3 Market segmentation, By Country

6.3.1 Germany

6.3.2 France

6.3.3 UK

6.3.4 Italy

6.3.5 Spain

6.3.6 Netherlands

6.3.7 Rest of Europe

  7. Cancer Biomarkers Market

7.1 Introduction

7.2 Oncology Biomarkers Market

7.3 Oncology biomarkers Discovery market

7.3.1 Genomics

7.3.2 Proteomics

7.3.3 Metabolomics

7.3.4 Transcriptomics

7.3.5 Other Omics

7.3.6 Imaging

7.4 Cancer Biomarkers Diagnostic Market

7.4.1 Immunohistochemical (IHC) tests

7.4.2 Molecular (DNA and genomic) diagnostic assays

7.4.3 Genetic and genomic markers

7.4.5 Proteomics

7.4.6 Flow cytometry

7.4.7 Stem cell markers

7.4.8 Monoclonal antibodies

7.4.9 Pharmacogenomics

7.4.10 DNA microarrays

7.4.11 IVD multivariate index assays (IVDMIA)

8. Competitive Landscape

8.1 Introduction

8.2 New product launches

8.3 Market strategies

8.4 Agreements, Partnerships & expansion

8.5 Mergers and Acquisitions

8.6 Market Share Analysis

  9. Key Vendors In Market

9.1 ACE Biosciences A/S (Denmark)

9.1.1 Company overview

9.1.2 Financial overview

9.1.3 Product portfolio

9.1.4 Business strategies

9.1.5 Recent developments

9.2 Affibody AB (Sweden)

9.2.1 Company overview

9.2.2 Financial overview

9.2.3 Product portfolio

9.2.4 Business strategies

9.2.5 Recent developments

9.3 Agendia N.V. (Netherlands)

9.3.1 Company overview

9.3.2 Financial overview

9.3.3 Product portfolio

9.3.4 Business strategies

9.3.5 Recent developments

9.4 Alphalyse A/S (Denmark)

9.4.1 Company overview

9.4.2 Financial overview

9.4.3 Product portfolio

9.4.4 Business strategies

9.4.5 Recent developments

9.5 Ani Biotech Oy (Finland)

9.5.1 Company overview

9.5.2 Financial overview

9.5.3 Product portfolio

9.5.4 Business strategies

9.5.5 Recent developments

9.6 Astrazeneca Plc (United Kingdom)

9.6.1 Company overview

9.6.2 Financial overview

9.6.3 Product portfolio

9.6.4 Business strategies

9.6.5 Recent developments

9.7 Bayer AG (Germany)

9.7.1 Company overview

9.7.2 Financial overview

9.7.3 Product portfolio

9.7.4 Business strategies

9.7.5 Recent developments

9.8 Biocartis SA (Switzerland)

9.8.1 Company overview

9.8.2 Financial overview

9.8.3 Product portfolio

9.8.4 Business strategies

9.8.5 Recent developments

9.9 Biomérieux SA (France)

9.9.1 Company overview

9.9.2 Financial overview

9.9.3 Product portfolio

9.9.4 Business strategies

9.9.5 Recent developments

9.10 Biosystems International (France)

9.10.1 Company overview

9.10.2 Financial overview

9.10.3Product portfolio

9.10.4 Business strategies

9.10.5 Recent developments

9.11 Boehringer Ingelheim Gmbh (Germany)

9.11.1 Company overview

9.11.2 Financial overview

9.11.3 Product portfolio

9.11.4 Business strategies

9.11.5 Recent developments

9.12 Dako Denmark A/S (Denmark)

9.12.1 Company overview

9.12.2 Financial overview

9.12.3 Product portfolio

9.12.4 Business strategies

9.12.5 Recent developments

9.13 Decode Genetics (Iceland)

9.13.1 Company overview

9.13.2 Financial overview

9.13.3 Product portfolio

9.13.4 Business strategies

9.13.5 Recent developments

9.14 Epigenomics AG (Germany)

9.14.1 Company overview

9.14.2 Financial overview

9.14.3 Product portfolio

9.14.4 Business strategies

9.14.5 Recent developments

9.15 F. Hoffmann-La Roche Ltd. (Switzerland)

9.15.1 Company overview

9.15.2 Financial overview

9.15.3 Product portfolio

9.15.4 Business strategies

9.15.5 Recent developments

9.16 GE Healthcare Ltd. (United Kingdom)

9.16.1 Company overview

9.16.2 Financial overview

9.16.3 Product portfolio

9.16.4 Business strategies

9.16.5 Recent developments

9.17 Genedata AG (Switzerland)

9.17.1 Company overview

9.17.2 Financial overview

9.17.3 Product portfolio

9.17.4 Business strategies

9.17.5 Recent developments

9.18 Glaxosmithkline, Plc (United Kingdom)

9.18.1 Company overview

9.18.2 Financial overview

9.18.3 Product portfolio

9.18.4 Business strategies

9.18.5 Recent developments

9.19 Novartis AG (Switzerland)

9.19.1 Company overview

9.19.2 Financial overview

9.19.3 Product portfolio

9.19.4 Business strategies

9.19.5 Recent developments

9.20 Pamgene International BV (Netherlands)

9.20.1 Company overview

9.20.2 Financial overview

9.20.3 Product portfolio

9.20.4 Business strategies

9.20.5 Recent developments

9.21 Philips Healthcare (Netherlands)

9.21.1 Company overview

9.21.2 Financial overview

9.21.3 Product portfolio

9.21.4 Business strategies

9.21.5 Recent developments

9.22 Sanofi (France)

9.22.1 Company overview

9.22.2 Financial overview

9.22.3 Product portfolio

9.22.4 Business strategies

9.22.5 Recent developments

9.23 Siemens Healthcare (Germany)

9.23.1 Company overview

9.23.2 Financial overview

9.23.3 Product portfolio

9.23.4 Business strategies

9.23.5 Recent developments

9.24 UCB S.A. (Belgium)

9.24.1 Company overview

9.24.2 Financial overview

9.24.3 Product portfolio

9.24.4 Business strategies

9.24.5 Recent developments